Sch-351125 and Sch-350634 Schering-Plough

Current Opinion in Investigational Drugs

Volumn 3, Issue 3, 2002, Pages 379-383

  Esté, José A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; ENFUVIRTIDE; LAMIVUDINE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; RANTES; SCH 350634; UNCLASSIFIED DRUG; ZIDOVUDINE;

AREA UNDER THE CURVE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MARKETING; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG QT SYNDROME; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

ANTI-HIV AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CYCLIC N-OXIDES; HIV INFECTIONS; HUMANS; PIPERAZINES; PIPERIDINES; PYRIDINES; RECEPTORS, CCR5; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036231411     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Schering-Plough reports 2000 second quarter earnings per share, reviews pharmaceutical research and business progress
2. Drug development pipeline: SC-351125
3. Retroviruses and Opportunistic Infections - Eighth Annual Conference (Part II), Chicago, IL, USA
4. American Chemical Society 221st National Meeting - Overnight Report (Part II), San Diego, CA, USA
5. Antiviral Research 14th International Conference - Overnight Report (Part III), Seattle, WA, USA
6. American Chemical Society 221st National Meeting (Part XIII). Inhibitors of HIV Entry: Potential New Therapies for Treatment of HIV Infection, San Diego, CA, USA
7. Drug development pipeline: SCH-C, SCH-D
8. Discovery of 4-[(Z)-(4-bromophenyl)-(ethoxyimino)methyl]-1′-[(2,4-dimethyl-3-pyridinyl) carbonyl]-4′-methyl-1,4′-bipiperidine N-oxide (SCH-351125): An orally bioavailable human CCR5 antagonist for the treatment of HIV infection
9. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifl uoro-methyl)phenyl]ethyl]-1-piperazinyl]-pieperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist
10. Interscience Conference on Antimicrobial Agents and chemotherapy - 41st Meeting (Part V) - Overnight Report, ICAAC Lecture and HIV Plenary Session, Chicago, IL, USA
11. Products in development: Product pipeline
12. Summary of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA
13. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo
14. Second generation CCR5 antagonist that inhibits HIV-1 entry
15. SCH-C, a CCR5 antagonist, has synergistic interactions with antiretrovirals from various classes
16. Schering-Plough: Santa smiles on SGP
17. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
18. HIV's response to a CCR5 inhibitor: I'd rather tighten than switch!
19. The role of CC chemokine receptor 5 in antiviral immunity
20. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS
21. SCH C: Safety and antiviral effects of a CCR5 receptor antagonist in HIV-1-infected subjects